| 2025-12-16 |
股东大会：
将于2026-01-09召开股东大会
会议内容 ▼▲
- 1.To approve the exercise of the Common Warrants (as defined below) issued by the Company on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of the Company’s Class A common stock under applicable rules and regulations of the New York Stock Exchange (the “NYSE”).
|
| 2025-12-12 |
详情>>
股本变动：
变动后总股本678.12万股
|
| 2025-12-03 |
详情>>
内部人交易：
Khalifa Sammy等共交易2笔
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-6.68美元,归母净利润-3966.7万美元,同比去年增长19.53%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘后发布财报
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-4.82美元,归母净利润-2860.9万美元,同比去年增长11.17%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-2.6美元,归母净利润-1539.4万美元,同比去年增长9.45%
|
| 2025-04-29 |
股东大会：
将于2025-06-27召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve one-year terms expiring in 2026;
2.To approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the “Plan”) to increase the number of shares of our common stock authorized for issuance under the Plan by 311,046 shares;
3.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2025-03-17 |
详情>>
业绩披露：
2024年年报每股收益-10.74美元,归母净利润-6322.3万美元,同比去年增长11.04%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-8.39美元,归母净利润-4929.7万美元,同比去年增长14.95%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-5.49美元,归母净利润-3220.6万美元,同比去年增长23.78%
|
| 2024-06-10 |
详情>>
拆分方案：
每30.0000合并分成1.0000股
|
| 2024-04-29 |
详情>>
业绩披露：
2024年一季报每股收益-0.1美元,归母净利润-1700.1万美元,同比去年增长36.85%
|
| 2024-04-23 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve one-year terms expiring in 2025.
2.To approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the “Plan”) to increase the number of shares of our common stock authorized for issuance under the Plan by 5,000,000 shares.
3.To approve an amendment to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of our issued and outstanding Class A common stock, par value $0.0001 per share (the “Class A common stock”), and Class B common stock, par value $0.0001 per share (the “Class B common stock” and, together with our Class A common stock, the “common stock”), at a ratio of not less than 1-for-5 and not greater than 1-for-30, with the exact ratio to be set within that range at the discretion of the Board of Directors (the “Board”) without further approval or authorization of our stockholders and with our Board able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion (the “Reverse Split Proposal”).
4.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2024-03-04 |
详情>>
业绩披露：
2023年年报每股收益-0.49美元,归母净利润-7107.1万美元,同比去年增长-1478.15%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.43美元,归母净利润-5796万美元,同比去年增长-454.78%
|
| 2023-07-28 |
详情>>
业绩披露：
2023年中报每股收益-0.33美元,归母净利润-4225.6万美元,同比去年增长-202.88%
|
| 2023-04-25 |
股东大会：
将于2023-06-01召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to serve one-year terms expiring in 2024;
2.To approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the “Plan”) to increase the number of shares of our common stock authorized for issuance under the Plan by 6,970,817 shares;
3.To approve an amendment to the Certificate of Incorporation of Vicarious Surgical Inc. (the “Certificate of Incorporation”) to include a provision eliminating or limiting monetary liability for certain officers for breach of the duty of care in certain actions;
4.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-01召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve one-year terms expiring in 2023;
2.To approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the “Plan”) to, among other things, increase the number of shares of our common stock authorized for issuance under the Plan by 6,590,000 shares;
3.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|